FTC v. Express Scripts, Inc.

Express Scripts, Inc., and its affiliated entities allegedly required them to adopt changes to their business practices that increase transparency and are expected to lower patients’ out-of-pocket costs for drugs like insulin by up to $7 billion over 10 years; companies are alleged to have misled millions of consumers seeking health insurance into purchasing indemnity, telemedicine, and health discount plans; substance-abuse treatment facilities allegedly used telemarketers to impersonate other facilities and funnel consumers with substance-abuse disorders from recommended, local facilities to their own.

Summary generated from official Federal Trade Commission press release